Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 23, 2025 08:19 ET | Source: Biomerica, Inc.

United Arab Emirates Ministry of Health and Prevention Approves Biomerica’s Fortel® Ulcer Test for Detection of H. pylori Infection

10-minute test enables detection of Helicobacter pylori, a leading cause of peptic ulcers, dyspepsia, and gastric cancerApproximately 80% of gastric cancer cases are linked to H. pylori infection; WHO...
February 22, 2024 05:50 ET | Source: Transparency Market Research

Helicobacter Pylori Non-invasive Testing Market to Exceed USD 788.2 million by 2031, with a CAGR of 4.2%: Transparency Market Research, Inc

Wilmington, Delaware, United States, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. -The global helicobacter pylori (H. Pylori) non-invasive testing market is estimated to surge...
January 23, 2024 08:19 ET | Source: Biomerica, Inc.

Diagnostics Industry Leader Jack Kenny Appointed as Chairman of the Board at Biomerica

Mr. Kenny has significant executive experience and a proven track record in medical diagnostics and healthcare Mr. Kenny most recently served as CEO of Meridian Bioscience where he successfully built...
October 09, 2023 08:04 ET | Source: The Insight Partners

Antibody Drug Conjugates Market Revenue to Hit $29.6 Billion, Globally, by 2030 – Exclusive Study by The Insight Partners

Pune, India, Oct. 09, 2023 (GLOBE NEWSWIRE) -- Antibody drug conjugates (ADC) are one of the fastest growing anticancer drugs. It is typically composed of a monoclonal antibody (mAbs) covalently...
March 02, 2023 09:55 ET | Source: The Insight Partners

Gastric Cancer Diagnostic Procedure Market Size Forecasts at 6.5% CAGR during (2022-2028) - Deep Dive Analysis of 18+ Countries across 5 Key Regions, 50+ Companies Scrutinized | The Insight Partners

New York, March 02, 2023 (GLOBE NEWSWIRE) -- According to The Insight Partners, “Gastric Cancer Diagnostic Procedure Market Size, Share, Growth, Trends and Global Forecasts to 2028 - COVID-19 Impact...
August 24, 2022 06:00 ET | Source: The Insight Partners

Helicobacter Pylori Non-invasive Testing Market Revenue to Cross $800.04Mn, Globally, by 2028 to Growing at 4.4% CAGR – Study by The Insight Partners

New York, Aug. 24, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Helicobacter Pylori (H. Pylori) Non-Invasive Testing Market Forecast to 2028 – COVID-19 Impact...
April 26, 2022 08:19 ET | Source: Biomerica, Inc.

Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population

Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major...
June 24, 2021 08:19 ET | Source: Biomerica, Inc.

Biomerica Signs Exclusive Distribution Agreement in Canada for its New and Proprietary Helicobacter Pylori (H. pylori) Test, hp+detect™

Prevalence of H. pylori infection in the United States is approximately 35% to 40% of the population IRVINE, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced...
July 27, 2020 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Increases Patient Access to Talicia® with EnvisionRx Formularies

Talicia® is the first and only FDA-approved rifabutin-based therapy for H. pylori infection designed as a first-line option to address the high and growing resistance of H. pylori to...
November 04, 2019 06:05 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults

RedHill plans to launch Talicia®1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults, targeting more than two million patients estimated to be treated for H. pylori infection...

Next Page keyboard_arrow_right